Evidence map›Paper›PMID 42006250›Full record

ArticleACS bio & med chem Au2026

High Drug Encapsulation Capacity in Cyclodextrin-Based Nanoparticles: Characterization and

Tomoki Kosugi, Mina Sakuragi, Madoka Toya, Tomoki Nishimura, Taiki Saito, Reina Kobayashi, Liliana de Campo, Kazuo Sakurai, Riku Kawasaki, Noriko Miyamoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS bio & med chem Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tomoki KosugiDepartment of Chemistry and Biochemistry, The University of Kitakyushu, 1-1, Hibikino, Wakamatsu, Kitakyushu, Fukuoka 808-0135, Japan.
Mina SakuragiFaculty of Engineering, Department of Nanoscience, Sojo University, 4-22-1, Ikeda, Nishi, Kumamoto 860-0082, Japan.ORCID https://orcid.org/0000-0002-6362-3673
Madoka ToyaDepartment of Applied Chemistry, Faculty of Engineering, Aichi Institute of Technology, 1247, Yachigusa, Yakusa-cho, Toyota, Aichi 470-0356, Japan.
Tomoki NishimuraDepartment of Chemistry and Materials Science, Shinshu University, 3-15-1, Tokida, Ueda, Nagano 386-8567, Japan.ORCID https://orcid.org/0000-0002-9034-3626
Taiki SaitoProgram of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, Hiroshima 739-8527, Japan.
Reina KobayashiDepartment of Applied Chemistry, Faculty of Engineering, Aichi Institute of Technology, 1247, Yachigusa, Yakusa-cho, Toyota, Aichi 470-0356, Japan.
Liliana de CampoAustralian Centre for Neutron Scattering, Australian Nuclear Science and Technology Organization (ANSTO), New Illawarra Road, Lucas Heights, New South Wales 2234, Australia.
Kazuo SakuraiDepartment of Chemistry and Biochemistry, The University of Kitakyushu, 1-1, Hibikino, Wakamatsu, Kitakyushu, Fukuoka 808-0135, Japan.ORCID https://orcid.org/0000-0002-9737-0061
Riku KawasakiProgram of Applied Chemistry, Graduate School of Advanced Science and Engineering, Hiroshima University, 1-4-1 Kagamiyama, Higashi-Hiroshima, Hiroshima 739-8527, Japan.
Noriko MiyamotoDepartment of Applied Chemistry, Faculty of Engineering, Aichi Institute of Technology, 1247, Yachigusa, Yakusa-cho, Toyota, Aichi 470-0356, Japan.ORCID https://orcid.org/0000-0002-6476-067X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insufficient drug encapsulation, typically at about 10 wt %, remains a major challenge in the design of nanotechnology-based drug delivery systems. In this study, we created cyclodextrin-based nanoparticles (CDNP_PEGs), synthesized by the hyperbranched polymerization of cyclodextrins using a diepoxy poly-(ethylene glycol) linker, which exhibited a high drug encapsulation capacity of up to 54 wt % using the xanthone derivative α-mangostin (MGS) as a model compound. Evaluation in a tumor-bearing mouse model indicated that a single intravenous administration via the tail vein induced a significantly greater antitumor effect compared with free MGS. These results demonstrate the potential of CDNP_PEGs as promising high-capacity carriers for the delivery of anticancer drugs.

Indexed as

antitumor drugsantitumor effectCD polymercyclodextrin (CD)drug delivery systemnanoparticlenanotechnology-based medicines

Identifiers

PMID42006250
PMCPMC13087803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.